- Market Cap
- —
- 1Y Performance
- -0.9%
- Avg Daily Volume
- 134.8K
52-Week Range
4.50(16 Oct 25)66.00(5 Nov 24)
Current 7.25 · position in 52-week range
| 23 Feb 2026 | 10:30:00 | First Asset Match auction nearing close |
| 16 Jan 2026 | 07:00:06 | Update re. review of previous financial position |
| 7 Jan 2026 | 07:00:07 | Secondary Trading Following Cancellation |
| 22 Dec 2025 | 16:08:04 | Result of General Meeting and Cancellation |
| 12 Jul 2026 | Annual Report and Accounts (to 2025-12-31) | |
| 2 Jul 2025 | Annual Report and Accounts (to 2024-12-31) | |
| 3 Apr 2024 | Annual Report and Accounts (to 2023-12-31) |
| 30 Sept 2025 | AIM movers: SEEEN grows revenues and Billington hit by delays | |
| 23 Sept 2024 | Maiden pre-tax profit | |
Tissue Regenix is a prominent player in the regenerative medicine industry, specializing in medical devices. The company has developed a unique decellularization technology that eliminates cellular components, including DNA, from soft tissue obtained from animals and humans, resulting in an acellular tissue.
| 23 Feb 2026 | 10:30:00 | First Asset Match auction nearing close |
| 16 Jan 2026 | 07:00:06 | Update re. review of previous financial position |
| 7 Jan 2026 | 07:00:07 | Secondary Trading Following Cancellation |
| 22 Dec 2025 | 16:08:04 | Result of General Meeting and Cancellation |
| 12 Jul 2026 | Annual Report and Accounts (to 2025-12-31) | |
| 2 Jul 2025 | Annual Report and Accounts (to 2024-12-31) | |
| 3 Apr 2024 | Annual Report and Accounts (to 2023-12-31) |
| 30 Sept 2025 | AIM movers: SEEEN grows revenues and Billington hit by delays | |
| 23 Sept 2024 | Maiden pre-tax profit | |
Tissue Regenix is a prominent player in the regenerative medicine industry, specializing in medical devices. The company has developed a unique decellularization technology that eliminates cellular components, including DNA, from soft tissue obtained from animals and humans, resulting in an acellular tissue.
| 8 Dec 2025 | 07:00:11 | Update re. proposed cancellation of shares |
| 10 Apr 2024 |
| Six consecutive periods of >20% growth |
| 18 Sept 2023 | Continuation of the positive momentum |
| 5 Apr 2023 | Turning profitable and cash-generative |
| 27 Sept 2022 | Operating leverage |
| 19 Jul 2022 | Strong 1H’22 sales suggest upside potential |
| 19 Apr 2022 | On pathway to sustainability |
| 8 Dec 2025 | 07:00:11 | Update re. proposed cancellation of shares |
| 10 Apr 2024 |
| Six consecutive periods of >20% growth |
| 18 Sept 2023 | Continuation of the positive momentum |
| 5 Apr 2023 | Turning profitable and cash-generative |
| 27 Sept 2022 | Operating leverage |
| 19 Jul 2022 | Strong 1H’22 sales suggest upside potential |
| 19 Apr 2022 | On pathway to sustainability |
| Issuer | Mkt cap | 1Y |
|---|---|---|
| £9.37bn | -0.2% | |
| £68m | -0.2% | |
| £11m | +0.5% | |
| £5m | -0.5% | |
| £346k | -0.7% | |
TRXTissue Regenix Group plc | £67 | -0.9% |
| Issuer | Mkt cap | 1Y |
|---|---|---|
| £9.37bn | -0.2% | |
| £68m | -0.2% | |
| £11m | +0.5% | |
| £5m | -0.5% | |
| £346k | -0.7% | |
TRXTissue Regenix Group plc | £67 | -0.9% |
